Jonathan E. Rosenberg

Jonathan E. Rosenberg, MD, is a Clinical Professor and Chief of the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center (MSK). He specializes in treating genitourinary cancers, particularly bladder, urethral, and penile cancers, and serves as the Enno W. Ercklentz, Jr. Chair. Prior to joining MSK in 2012, he held leadership roles at Dana-Farber/Brigham and Women’s Cancer Center of Harvard Medical School.

• Education: MD from Harvard Medical School
• Training: Residency in Internal Medicine at NewYork-Presbyterian/Weill Cornell Medical Center, Fellowship in Medical Oncology at University of California San Francisco Medical Center

Dr. Rosenberg focuses on advancing immunotherapy and targeted therapy for bladder cancer. He led clinical trials resulting in the first FDA drug approvals for urothelial cancer in over 20 years and Breakthrough Therapy Designations. His research emphasizes biomarker testing to personalize treatment and improve patient outcomes.

Scientific Awards and Recognitions:

• Castle Connolly: America’s Top Doctor (2025, 2024, 2023)
• Top Doctors New York Metro Area (2023)

He actively participates in national committees and has presented extensively on bladder cancer and immunotherapy at international meetings. Disclosures include professional services and activities with pharmaceutical and biotech companies, though no uncompensated relationships are explicitly stated.